Written exposure therapy for veterans with co-occurring substance use disorders and PTSD: Study design of a randomized clinical trial.

Autor: Meshberg-Cohen S; Yale University School of Medicine, Department of Psychiatry, United States of America; VA Connecticut Healthcare System, United States of America. Electronic address: sarah.meshberg-cohen@yale.edu., Cook JM; Yale University School of Medicine, Department of Psychiatry, United States of America., Bin-Mahfouz A; Yale University School of Medicine, Department of Psychiatry, United States of America; VA Connecticut Healthcare System, United States of America., Petrakis IL; Yale University School of Medicine, Department of Psychiatry, United States of America; VA Connecticut Healthcare System, United States of America.
Jazyk: angličtina
Zdroj: Contemporary clinical trials [Contemp Clin Trials] 2024 Apr; Vol. 139, pp. 107475. Date of Electronic Publication: 2024 Feb 15.
DOI: 10.1016/j.cct.2024.107475
Abstrakt: There are high rates of posttraumatic stress disorder (PTSD) among treatment-seeking veterans with substance use disorders (SUD). While addiction programs traditionally do not address PTSD, there is evidence that trauma treatments for individuals with this comorbidity have improved PTSD and SUD outcomes. Written exposure therapy (WET), a five-session evidence-based psychotherapy (EBP) for PTSD, has high patient satisfaction, and lower dropout compared to other EBPs for PTSD. WET may be ideally suited for clinical settings that may not have the trauma expertise found in PTSD specialty clinics, given it requires less training time, treatment sessions, preparation time, and therapist involvement than existing EBPs, and no homework assignments. This paper describes the design, methodology, and protocol of a randomized clinical trial to evaluate whether treatment as usual (TAU) plus WET (n = 51) is superior to TAU plus a neutral topic writing condition (n = 51) on both PTSD and addiction outcomes for veterans in SUD treatment. The primary hypothesis is that participants assigned to TAU+WET, compared to those in TAU+ neutral topic writing, will report reduced symptoms of PTSD. The secondary hypothesis is that veterans receiving WET will have greater decreases in number of days of substance use compared to TAU+ neutral topic controls at follow-up. Assessments will take place at baseline, post-treatment, 8-week, and 12-week follow-up. Exploratory aims will examine the association between heart rate variability and treatment outcomes. If results prove promising, they will support WET as an effective brief, easy to disseminate, adjunct to current SUD treatment for veterans with comorbid PTSD. Trial registration: ClinicalTrials.gov ID NCT05327504.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Meshberg-Cohen, Dr. Cook, and Ms. Bin-Mahfouz have no potential conflicts of interest or disclosures to report. Dr. Ismene Petrakis has received in kind (medications) support for research studies from Alkermes and BioXcel Therapeutics. Dr. Petrakis is co-Editor for Journal of Addiction Medicine (JAM). Dr. Petrakis has received textbook royalties from MacGraw/Hill. Dr. Ismene Petrakis also reports Patents and Inventions: (1) Arias A, Petrakis I, Krystal JH. – Composition and methods to treat addiction. Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research. (2) Gihyun, Yoon, Petrakis I, Krystal JH – Compounds, Compositions and Methods for Treating or Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552, filed on January10, 2017 by Yale University Office of Cooperative Research OCR 7088 US01.
(Published by Elsevier Inc.)
Databáze: MEDLINE
Externí odkaz: